Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE

Exclusion Criteria

• •Pregnancy or breast-feeding
• •Any clinically significant medical condition or medical history that, in the opinion of the Investigator or Sponsor, would interfere with the subject's safety or ability to participate in the study
• •Any laboratory parameter abnormality that, in the opinion of the Investigator, is clinically significant and relevant for this study
• •Severe hypersensitivity to multiple medicinal products or severe hypersensitivity/ anaphylaxis with unclear etiology
• •Use of C1-INH within 14 days or use of androgens or tranexamic acid within 28 days prior to the Screening visit for prophylaxis of HAE attacks, or initiation of these drugs during the study
• •Current participation in any other investigational drug study or received another investigational drug within 30 days of the Screening visit
• •Prior enrollment in a BCX7353 study